Hyperkalemia — Emergency Management

Key Points

• Treat severe hyperkalemia or ECG toxicity urgently even if laboratory confirmation is still being repeated.
• IV calcium stabilizes the myocardium but does not lower serum potassium.
• Insulin plus dextrose is a core shifting therapy and requires prolonged glucose surveillance.
• Nebulized albuterol is an adjunct, not reliable monotherapy for severe hyperkalemia.
• Do not use IV bicarbonate routinely unless there is a relevant acid-base indication.
• Definitive treatment requires potassium removal, not only intracellular shifting.
• ECG findings do not correlate reliably with the exact potassium concentration.
• Recheck potassium for rebound and identify the medication, renal, endocrine, or tissue-breakdown cause.

Algorithm

1. Place the patient on cardiac monitoring, obtain a 12-lead ECG, repeat potassium if artifact is possible, and assess renal function and acid-base status.
2. If ECG toxicity or severe instability is present, give IV calcium immediately and repeat if ECG abnormalities persist.
3. Give insulin plus dextrose and add nebulized albuterol for severe or high-risk hyperkalemia.
4. Treat major metabolic acidosis when clinically indicated and stop exogenous potassium or offending medications.
5. Remove potassium using diuresis when appropriate, a potassium binder in selected patients, and dialysis when medical therapy is inadequate or renal failure is severe.
6. Recheck potassium at short intervals after therapy and monitor glucose closely for several hours after insulin.
7. Look for rebound, ongoing tissue breakdown, missed dialysis, or unrecognized medication contributors.
8. Before discharge, create a renal, medication, diet, and follow-up plan tailored to recurrence risk.

Clinical Synopsis & Reasoning

Confirm true hyperkalemia while treating immediately if the patient has severe elevation, characteristic ECG toxicity, profound weakness, or cardiac instability. Pseudohyperkalemia can result from hemolysis, difficult phlebotomy, severe thrombocytosis, or leukocytosis, but a suspicious specimen should not delay treatment when the clinical risk is high. Obtain an urgent 12-lead ECG for significant hyperkalemia, recognizing that ECG sensitivity is limited and life-threatening hyperkalemia can exist without classic changes. Typical findings include peaked T waves, PR prolongation, loss of P waves, QRS widening, sine-wave morphology, ventricular arrhythmia, and asystole, but potassium level does not reliably predict the sequence. Common causes include AKI or CKD, RAAS inhibitors, mineralocorticoid antagonists, potassium supplements, trimethoprim, NSAIDs, tissue breakdown, acidosis, insulin deficiency, adrenal insufficiency, and laboratory artifact. Evaluate renal function, acid-base status, glucose, medications, and evidence of rhabdomyolysis or hemolysis. Severe hyperkalemia is commonly defined at 6.5 mmol/L or higher, though lower levels may require aggressive therapy when there are ECG changes, rapid rise, or high-risk clinical features. Continuous cardiac monitoring is appropriate for severe disease and for significant ECG abnormalities.

Treatment Strategy & Disposition

If ECG changes attributable to hyperkalemia are present, give IV calcium promptly to stabilize the cardiac membrane. Calcium does not lower potassium, so it must be followed by potassium-shifting and removal strategies. IV regular insulin with dextrose is a rapid and reliable intracellular shift therapy, but delayed hypoglycemia is common enough that serial glucose monitoring for several hours is mandatory. Nebulized albuterol is an effective adjunct, particularly in severe hyperkalemia, but should not be used as the only shifting therapy. IV bicarbonate should not be used routinely for acute hyperkalemia, although it may help selected patients with clinically important metabolic acidosis. Remove potassium by treating the cause, promoting renal excretion when kidney function and volume status permit, using modern potassium binders in selected patients, and initiating dialysis for refractory severe hyperkalemia, severe renal failure, or ongoing potassium release when medical therapy is inadequate. The 2023 UK Kidney Association guideline recommends sodium zirconium cyclosilicate in emergency management of severe hyperkalemia and considers patiromer an option in acute hyperkalemia, but binders do not replace immediate membrane stabilization and shifting therapy. Recheck potassium after treatment and again after the shifting effect wanes because rebound is common. Stop contributing medications temporarily when appropriate and establish a prevention plan before discharge.

Epidemiology / Risk Factors

• CKD, AKI, diabetes, heart failure, and RAAS-inhibiting medications are common risk contexts.
• The prevalence of hyperkalemia rises as GFR falls and with combinations of RAAS blockade, MRA therapy, or potassium supplements.
• Tissue breakdown from rhabdomyolysis, tumor lysis, burns, or hemolysis can cause rapid dangerous potassium release.
• Metabolic acidosis and insulin deficiency shift potassium out of cells and can magnify the serum elevation.
• Recurrence is common unless the underlying medication, renal, endocrine, dietary, or dialysis issue is addressed.

Investigations

ECG Progression (Typical)

Pharmacology

Prognosis / Complications

• Severe hyperkalemia can progress rapidly to ventricular fibrillation, pulseless electrical activity, or asystole.
• Outcome is best when cardiac toxicity is recognized before arrest and definitive potassium removal is achieved.
• Rebound is common after insulin and beta-agonist effects wear off if potassium has not been removed from the body.
• Hypoglycemia is an important treatment-related complication, particularly in advanced kidney disease.
• Long-term prognosis depends heavily on whether kidney function and guideline-directed cardiorenal therapies can be safely optimized without recurrent hyperkalemia.

Patient Education / Counseling

• Review all prescription drugs, over-the-counter NSAIDs, salt substitutes, supplements, and herbal products that may contain potassium or impair potassium excretion.
• Do not stop beneficial heart-failure or kidney medications permanently without a clinician-led plan; potassium-lowering strategies may allow safe continuation.
• Seek urgent care for severe weakness, palpitations, syncope, chest discomfort, or a laboratory potassium result in the emergency range.
• If on dialysis, emphasize adherence to the schedule and prompt contact for missed treatments or access problems.
• Arrange repeat potassium and kidney-function testing after medication changes or an acute episode.

Notes

The emergency sequence is membrane stabilization, intracellular shift, and potassium removal. Failure to complete the third step is why patients can deteriorate again after an apparently successful first hour. Insulin and albuterol redistribute potassium but do not eliminate it. The potassium should therefore be rechecked after the initial response and again as the temporizing effect wanes. Glucose monitoring must continue even after the potassium has improved because insulin-related hypoglycemia can be delayed. Patients with severe kidney failure, missed dialysis, ongoing tissue breakdown, or recurrent rebound should be discussed early with nephrology for definitive removal.

References

1. UK Kidney Association Clinical Practice Guideline: Treatment of Acute Hyperkalaemia in Adults — Link